Skip to content

Establishing how many patients with HIV are infected with Kala Azar but show no symptoms, bit then go on to develop symptoms over 18 months.

Prevalence of asymptomatic visceral leishmaniasis (VL) infection in HIV positive patients and risk factors for progression to symptomatic VL in highly endemic districts of Bihar

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/03/008120
Enrollment
1000
Registered
2017-03-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- HIV positive patients under routine monitoring care at ART centres

Interventions

None listed

Sponsors

Medecins Sans Frontires India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Registered ART/pre-ART patients with either a new or established diagnosis of HIV 2 Written consent

Exclusion criteria

Exclusion criteria: 1 Previous treatment for, or current diagnosis of symptomatic visceral leishmaniasis or PKDL

Design outcomes

Primary

MeasureTime frame
- Determine prevalence of asymptomatic VL cases in HIV cases registered at ART centres from highly VL endemic areas - Determine the rate of conversion of asymptomatic VL cases into symptomatic VL over a period of 18 months. Timepoint: - Determine prevalence of asymptomatic VL cases in HIV cases registered at ART centres from highly VL endemic areas - Determine the rate of conversion of asymptomatic VL cases into symptomatic VL over a period of 18 months.

Secondary

MeasureTime frame
- To correlate results of rk39 ICT with qPCR in PLHIV. - To determine risk factors for progression of asymptomatic cases to symptomatic VL over a follow up period of 18 months in PLHIV. Timepoint: 18 months

Countries

India

Contacts

Public ContactDr Sakib Burza

Medecins Sans Frontières

sakib.burza@barcelona.msf.org9871258886

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 11, 2026